Immunogenicity and safety of GSK Biologicals' candidate tuberculosis (TB) vaccine (692342) when administered to healthy adults aged 21 to 40 years.

Trial Profile

Immunogenicity and safety of GSK Biologicals' candidate tuberculosis (TB) vaccine (692342) when administered to healthy adults aged 21 to 40 years.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2009

At a glance

  • Drugs GSK 692342 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jul 2008 The expected completion date for this trial has been extended from Nov 2008 to Dec 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top